Press coverage about Arrowhead Pharmaceuticals (NASDAQ:ARWR) has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.4809380525716 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™ (finance.yahoo.com)
- Arrowhead Pharmaceuticals (ARWR) Upgraded to Buy at ValuEngine (americanbankingnews.com)
- Arrowhead Pharmaceuticals Corp (ARWR) Announces Multiple Presentations at The International Liver Congress (streetinsider.com)
- Arrowhead Pharmaceuticals, Inc. (ARWR) stock price ends at $7.21 with performance of 7.29% on volume of 1562927 … (nasdaqexpress.com)
- Top Stocks Under $10 (forbes.com)
Shares of Arrowhead Pharmaceuticals stock traded down $0.26 on Thursday, reaching $6.85. The company’s stock had a trading volume of 1,186,118 shares, compared to its average volume of 1,929,646. The firm has a market cap of $580.60, a price-to-earnings ratio of -14.57 and a beta of 2.36. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $8.09. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.03.
ARWR has been the subject of a number of analyst reports. BidaskClub raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Cantor Fitzgerald set a $2.00 price objective on Arrowhead Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, December 12th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 19th. B. Riley initiated coverage on Arrowhead Pharmaceuticals in a research report on Friday, January 5th. They set a “neutral” rating and a $3.00 price objective for the company. Finally, ValuEngine raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $6.30.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, March 27th. The stock was sold at an average price of $8.00, for a total value of $160,000.00. Following the completion of the sale, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $2,646,520. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $7.43, for a total value of $743,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,194,789 shares of the company’s stock, valued at approximately $16,307,282.27. The disclosure for this sale can be found here. In the last three months, insiders sold 440,000 shares of company stock valued at $3,266,600. Corporate insiders own 4.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2018/04/05/arrowhead-pharmaceuticals-arwr-earns-news-impact-rating-of-0-14/2027241.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.